Immune therapy scientists discover distinct cells that block cancer-fighting immune cells

February 06, 2017

(TORONTO, Canada - Feb. 6, 2017) - Princess Margaret Cancer Centre scientists have discovered a distinct cell population in tumours that inhibits the body's immune response to fight cancer.

The findings, published online today in Nature Medicine, are critical to understanding more about why patients do or do not respond to immune therapies, says principal investigator Pamela Ohashi, Director, Tumour Immunotherapy Program at the cancer centre, University Health Network. Dr. Ohashi holds a Canada Research Chair in Autoimmunity and Tumour Immunity. She is also a Professor at University of Toronto in the Departments of Medical Biophysics and Immunology.

"We've uncovered a potential new approach to modulate the immune response to cancer," says Dr. Ohashi. "By looking at tumour biology from this different perspective we'll have a better understanding of the barriers that prevent a strong immune response. This can help advance drug development to target these barriers."

The research team with international collaborators analysed more than 100 patient samples from ovarian and other cancer types to discover a distinct population of cells found in some tumours. This population of cells suppresses the growth of cancer-fighting immune cells, thereby limiting the ability of the immune system to fight off cancer.

For patients, down the road Dr. Ohashi envisions a new era of combined therapies to simultaneously target and kill these suppressive cells while augmenting the immune response against cancer. "This would really strengthen the way clinicians can treat cancer using immune therapy, which holds so much promise for patients."

The team's next avenue of research will be focused on identifying a "biomarker" that can identify this distinct suppressive cell elsewhere in the body - for example, in blood or other samples - as a potential predictive clinical tool to determine when these cells are present in patients, which currently cannot be done.

"That knowledge will guide clinical decisions to personalize cancer treatment to unleash an individual's immune response," says Dr. Ohashi. "We need to identify ways to track these cells and find another source and ways to grow these cells for further study."
-end-
For many years, Dr. Ohashi's team has been studying tumor-infiltrating lymphocytes (TILs), which are the cell type known to kill cancer cells. Patients with TILs do much better because they already have cancer-fighting cells in their tumours. Read more about the Tumour Immunotherapy Program at http://www.pm-tumorimmunotherapyprogram.ca/

The research published today was funded by the Canadian Institutes of Health Research and The Princess Margaret Cancer Foundation.

About Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to http://www.theprincessmargaret.ca or http://www.uhn.ca .

University Health Network

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.